Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
full spectrum microbiota (CP101) / Finch Therap
PRISM4, NCT05153499: A Trial of CP101 for the Prevention of Recurrent CDI	Terminated	3	19	Canada, US	CP101, Placebo	Finch Research and Development LLC.	Recurrent C. Difficile Infection	02/23	02/23
NCT05852574: CP101 for the Treatment of Ulcerative Colitis	Active, not recruiting	1	30	US	CP-101, CP-101 + Placebo	Brigham and Women's Hospital	Ulcerative Colitis	11/24	06/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
full spectrum microbiota (CP101) / Finch Therap
PRISM4, NCT05153499: A Trial of CP101 for the Prevention of Recurrent CDI	Terminated	3	19	Canada, US	CP101, Placebo	Finch Research and Development LLC.	Recurrent C. Difficile Infection	02/23	02/23
NCT05852574: CP101 for the Treatment of Ulcerative Colitis	Active, not recruiting	1	30	US	CP-101, CP-101 + Placebo	Brigham and Women's Hospital	Ulcerative Colitis	11/24	06/25